| Year |
Citation |
Score |
| 2023 |
Pinto JV, Crippa JAS, Ceresér KM, Vianna-Sulzbach MF, Silveira Júnior ÉM, Santana da Rosa G, Testa da Silva MG, Hizo GH, Simão Medeiros L, Santana de Oliveira CE, Bristot G, Campos AC, Guimarães FS, Hallak JEC, Zuardi AW, et al. Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 7067437231209650. PMID 37920963 DOI: 10.1177/07067437231209650 |
0.428 |
|
| 2023 |
Simei JLQ, Souza JDR, Lisboa JR, Campos AC, Guimarães FS, Zuardi A, Crippa JAS. Does the "Entourage Effect" in Cannabinoids Exist? A Narrative Scoping Review. Cannabis and Cannabinoid Research. PMID 37535820 DOI: 10.1089/can.2023.0052 |
0.412 |
|
| 2023 |
Crippa JAS, Guimarães FS, Zuardi AW, Hallak JEC. Prof. Dr Raphael Mechoulam, Cannabis and Cannabinoids Research Pioneer (November 05, 1930 - March 09, 2023) and his legacy for the Brazilian Pharmacology. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999). PMID 37243978 DOI: 10.47626/1516-4446-2023-0047 |
0.368 |
|
| 2022 |
Souza JDR, Pacheco JC, Rossi GN, de-Paulo BO, Zuardi AW, Guimarães FS, Hallak JEC, Crippa JA, Dos Santos RG. Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022). Pharmaceutics. 14. PMID 36559092 DOI: 10.3390/pharmaceutics14122598 |
0.459 |
|
| 2022 |
Souza JDS, Zuardi AW, Guimarães FS, Osório FL, Loureiro SR, Campos AC, Hallak JEC, Dos Santos RG, Machado Silveira IL, Pereira-Lima K, Pacheco JC, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, et al. Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic. Frontiers in Pharmacology. 13: 856846. PMID 36263136 DOI: 10.3389/fphar.2022.856846 |
0.471 |
|
| 2022 |
Pedrazzi JFC, Ferreira FR, Silva-Amaral D, Lima DA, Hallak JEC, Zuardi AW, Del-Bel EA, Guimarães FS, Costa KCM, Campos AC, Crippa ACS, Crippa JAS. Cannabidiol for the treatment of autism spectrum disorder: hope or hype? Psychopharmacology. 239: 2713-2734. PMID 35904579 DOI: 10.1007/s00213-022-06196-4 |
0.444 |
|
| 2022 |
Souza JDS, Fassoni-Ribeiro M, Batista RM, Ushirohira JM, Zuardi AW, Guimarães FS, Campos AC, Osório FL, Elias D, Souza CS, Fassoni AA, Hallak JEC, Crippa JAS. Case Report: Cannabidiol-Induced Skin Rash: A Case Series and Key Recommendations. Frontiers in Pharmacology. 13: 881617. PMID 35662726 DOI: 10.3389/fphar.2022.881617 |
0.392 |
|
| 2022 |
Bolsoni LM, Crippa JAS, Hallak JEC, Guimarães FS, Zuardi AW. The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999). PMID 35293520 DOI: 10.1590/1516-4446-2021-2317 |
0.414 |
|
| 2022 |
Bolsoni LM, Crippa JAS, Hallak JEC, Guimarães FS, Zuardi AW. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology. PMID 35029706 DOI: 10.1007/s00213-021-06043-y |
0.474 |
|
| 2021 |
Crippa JAS, Pacheco JC, Zuardi AW, Guimarães FS, Campos AC, Osório FL, Loureiro SR, Dos Santos RG, Souza JDS, Ushirohira JM, Ferreira RR, Mancini Costa KC, Scomparin DS, Scarante FF, Pires-Dos-Santos I, et al. Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Cannabis and Cannabinoid Research. PMID 34619044 DOI: 10.1089/can.2021.0093 |
0.466 |
|
| 2021 |
Crippa JAS, Zuardi AW, Guimarães FS, Campos AC, de Lima Osório F, Loureiro SR, Dos Santos RG, Souza JDS, Ushirohira JM, Pacheco JC, Ferreira RR, Mancini Costa KC, Scomparin DS, Scarante FF, Pires-Dos-Santos I, et al. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial. Jama Network Open. 4: e2120603. PMID 34387679 DOI: 10.1001/jamanetworkopen.2021.20603 |
0.387 |
|
| 2021 |
Crippa JA, Pereira Junior LC, Pereira LC, Zimmermann PM, Brum Junior L, Rechia LM, Dias I, Hallak JE, Campos AC, Guimarães FS, Queiroz RH, Zuardi AW. Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999). PMID 34076067 DOI: 10.1590/1516-4446-2020-1684 |
0.4 |
|
| 2021 |
Pacheco JC, Souza JDS, Hallak JEC, Osório FL, Campos AC, Guimarães FS, Zuardi AW, Crippa JAS. Cannabidiol as a Treatment for Mental Health Outcomes Among Health Care Workers During the Coronavirus Disease Pandemic. Journal of Clinical Psychopharmacology. 41: 327-329. PMID 33843818 DOI: 10.1097/JCP.0000000000001405 |
0.349 |
|
| 2020 |
Linares IMP, Nardi AE, Guimarães FS, Arrais KC, Chagas MH, Osório FL, Hallak JE, Zuardi AW, Coimbra NC, Crippa JA. Increased body sway in phobic patients exposed to images of spiders. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999). PMID 33331404 DOI: 10.1590/1516-4446-2020-1466 |
0.383 |
|
| 2020 |
Crippa JAS, Zuardi AW, Hallak JEC, Miyazawa B, Bernardo SA, Donaduzzi CM, Guzzi S, Favreto WAJ, Campos A, Queiroz MEC, Guimarães FS, da Rosa Zimmermann PM, Rechia LM, Jose Tondo Filho V, Brum Junior L. Oral Cannabidiol Does Not Convert to Δ-THC or Δ-THC in Humans: A Pharmacokinetic Study in Healthy Subjects. Cannabis and Cannabinoid Research. 5: 89-98. PMID 32322680 DOI: 10.1089/can.2019.0024 |
0.433 |
|
| 2020 |
Dos Santos RG, Guimarães FS, Crippa JAS, Hallak JEC, Rossi GN, Rocha JM, Zuardi AW. Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. Expert Opinion On Drug Metabolism & Toxicology. PMID 32271618 DOI: 10.1080/17425255.2020.1754793 |
0.425 |
|
| 2020 |
Crippa JA, de Lima Osório F, Hallak J, Guimarães FS, Zuardi AW. Cannabinoids for the treatment of mental disorders. The Lancet. Psychiatry. 7: 125-126. PMID 31981533 DOI: 10.1016/s2215-0366(19)30516-4 |
0.395 |
|
| 2019 |
Ferreira-Junior NC, Campos AC, Guimarães FS, Del-Bel E, Zimmermann PMDR, Brum Junior L, Hallak JE, Crippa JA, Zuardi AW. Biological bases for a possible effect of cannabidiol in Parkinson's disease. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999). PMID 31314869 DOI: 10.1590/1516-4446-2019-0460 |
0.396 |
|
| 2019 |
Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms? European Archives of Psychiatry and Clinical Neuroscience. PMID 30706171 DOI: 10.1007/s00406-019-00982-6 |
0.44 |
|
| 2018 |
Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimarães FS, Crippa JA. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999). PMID 30328956 DOI: 10.1590/1516-4446-2017-0015 |
0.461 |
|
| 2018 |
Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Frontiers in Immunology. 9: 2009. PMID 30298064 DOI: 10.3389/fimmu.2018.02009 |
0.474 |
|
| 2018 |
Linares IMP, Guimaraes FS, Eckeli A, Crippa ACS, Zuardi AW, Souza JDS, Hallak JE, Crippa JAS. No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Frontiers in Pharmacology. 9: 315. PMID 29674967 DOI: 10.3389/Fphar.2018.00315 |
0.45 |
|
| 2018 |
Crippa JA, Zuardi AW, Guimaraes FS. 17.4 POSSIBLE MECHANISMS INVOLVED IN THE ANTIPSYCHOTIC EFFECTS OF CANNABIDIOL (CBD) Schizophrenia Bulletin. 44: S28-S28. DOI: 10.1093/Schbul/Sby014.068 |
0.46 |
|
| 2017 |
Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimarães FS, Crippa JAS. Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. Frontiers in Pharmacology. 8: 259. PMID 28553229 DOI: 10.3389/Fphar.2017.00259 |
0.484 |
|
| 2016 |
Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JC, Crippa JA, Zuardi AW, Mechoulam R, Guimarães FS. Correction: Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects. Plos One. 11: e0162087. PMID 27560809 DOI: 10.1371/journal.pone.0162087 |
0.598 |
|
| 2016 |
Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JC, Crippa JA, Zuardi AW, Mechoulam R, Guimarães FS. Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects. Plos One. 11: e0158779. PMID 27416026 DOI: 10.1371/Journal.Pone.0158779 |
0.66 |
|
| 2016 |
Linares I, Zuardi AW, Pereira LCG, Queiroz RHC, Mechoulam R, Guimarães FS, Crippa JAS. Cannabidiol presents an inverted U-shaped dose-response curve in the simulated public speaking test European Neuropsychopharmacology. 26. DOI: 10.1016/S0924-977X(16)31702-3 |
0.4 |
|
| 2016 |
Linares I, Guimarães FS, Eckeli A, Zuardi AW, Souza JDS, Hallak JEC, Crippa JAS. Lack of cannabidiol effects on sleep-wake cycle in healthy patients European Neuropsychopharmacology. 26. DOI: 10.1016/S0924-977X(16)31310-4 |
0.375 |
|
| 2015 |
Stern CA, Gazarini L, Vanvossen AC, Zuardi AW, Galve-Roperh I, Guimaraes FS, Takahashi RN, Bertoglio LJ. Δ(9)-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 958-65. PMID 25799920 DOI: 10.1016/J.Euroneuro.2015.02.001 |
0.448 |
|
| 2015 |
Chaves C, Marque CR, Maia-de-Oliveira JP, Wichert-Ana L, Ferrari TB, Santos AC, Araújo D, Machado-de-Sousa JP, Bressan RA, Elkis H, Crippa JA, Guimarães FS, Zuardi AW, Baker GB, Dursun SM, et al. Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia. Schizophrenia Research. 161: 439-45. PMID 25497439 DOI: 10.1016/J.Schres.2014.11.031 |
0.469 |
|
| 2014 |
Batalla A, Crippa JA, Busatto GF, Guimaraes FS, Zuardi AW, Valverde O, Atakan Z, McGuire PK, Bhattacharyya S, Martín-Santos R. Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review. Current Pharmaceutical Design. 20: 2168-85. PMID 23829359 DOI: 10.2174/13816128113199990432 |
0.421 |
|
| 2014 |
Stern CA, Gazarmi L, Vanvossen AC, Zuardi AW, Guimarães FS, Takahashi RN, Bertoglio LJ. P.1.j.006 Involvement of the prelimbic cortex in the disruptive effect of cannabidiol on fear memory reconsolidation European Neuropsychopharmacology. 24. DOI: 10.1016/S0924-977X(14)70511-5 |
0.369 |
|
| 2013 |
Campos AC, de Paula Soares V, Carvalho MC, Ferreira FR, Vicente MA, Brandão ML, Zuardi AW, Zangrossi H, Guimarães FS. Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats. Psychopharmacology. 226: 13-24. PMID 23007604 DOI: 10.1007/S00213-012-2878-7 |
0.454 |
|
| 2012 |
Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimarães FS. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Current Pharmaceutical Design. 18: 5131-40. PMID 22716160 DOI: 10.2174/138161212802884681 |
0.508 |
|
| 2011 |
Zuardi AW, Guimarães FS, Hallak JE, Crippa JA. Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning? Expert Review of Neurotherapeutics. 11: 1111-4. PMID 21797651 DOI: 10.1586/ern.11.89 |
0.434 |
|
| 2010 |
Trzesniak C, Uchida RR, Araújo D, Guimarães FS, Freitas-Ferrari MC, Filho AS, Santos AC, Busatto GF, Zuardi AW, Del-Ben CM, Graeff FG, Crippa JA. (1)H magnetic resonance spectroscopy imaging of the hippocampus in patients with panic disorder. Psychiatry Research. 182: 261-5. PMID 20488674 DOI: 10.1016/J.Pscychresns.2010.03.008 |
0.423 |
|
| 2010 |
Soares Vde P, Campos AC, Bortoli VC, Zangrossi H, Guimarães FS, Zuardi AW. Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behavioural Brain Research. 213: 225-9. PMID 20457188 DOI: 10.1016/J.Bbr.2010.05.004 |
0.445 |
|
| 2010 |
Marque C, Chaves C, Wichert-Ana L, Crippa JAS, Zuardi AW, Baker GB, Guimarães FS, Dursun SM, Hallak JEC. P.1.e.004 Effects of minocycline on regional cerebral blood flow in schizophrenia European Neuropsychopharmacology. 20. DOI: 10.1016/S0924-977X(10)70383-7 |
0.399 |
|
| 2007 |
Hallak JE, Crippa JA, Pinto JP, Machado de Sousa JP, Trzesniak C, Dursun SM, McGuire P, Deakin JF, Zuardi AW. Total agenesis of the corpus callosum in a patient with childhood-onset schizophrenia. Arquivos De Neuro-Psiquiatria. 65: 1216-9. PMID 18345433 DOI: 10.1590/S0004-282X2007000700024 |
0.541 |
|
| 2006 |
Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Mã©Dicas E Biolã³Gicas / Sociedade Brasileira De BiofãSica ... [Et Al.]. 39: 421-9. PMID 16612464 DOI: 10.1590/S0100-879X2006000400001 |
0.52 |
|
| 2005 |
Dursun SM, Hallak JE, Haddad P, Leahy A, Byrne A, Strickland PL, Anderson IM, Zuardi AW, Deakin JF. Clozapine monotherapy for catatonic schizophrenia: should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index? Journal of Psychopharmacology (Oxford, England). 19: 432-3. PMID 15983003 DOI: 10.1177/0269881105053313 |
0.546 |
|
| 2005 |
Guarnieri R, Wichert-Ana L, Hallak JE, Velasco TR, Walz R, Kato M, Alexandre V, Terra-Bustamante VC, Bianchin MM, Zuardi AW, Deakin JF, Sakamoto AC. Interictal SPECT in patients with mesial temporal lobe epilepsy and psychosis: a case-control study. Psychiatry Research. 138: 75-84. PMID 15708303 DOI: 10.1016/J.Pscychresns.2004.10.003 |
0.548 |
|
| 2004 |
Guimarães VMC, Zuardi AW, Del Bel EA, Guimarães FS. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum Life Sciences. 75: 633-638. PMID 15158372 DOI: 10.1016/J.Lfs.2004.01.015 |
0.424 |
|
| 2004 |
Crippa JA, Uchida R, Busatto GF, Guimarães FS, Del-Ben CM, Zuardi AW, Santos AC, Araújo D, McGuire PK, Graeff FG. The size and prevalence of the cavum septum pellucidum are normal in subjects with panic disorder. Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Mã©Dicas E Biolã³Gicas / Sociedade Brasileira De BiofãSica ... [Et Al.]. 37: 371-4. PMID 15060705 DOI: 10.1590/S0100-879X2004000300013 |
0.434 |
|
| 2003 |
Hallak JE, Dursun SM, Guarnieri R, Almeida E, Rezeck K, Crippa JA, Sakamoto AC, Zuardi AW, Deakin JF. Olanzapine for recurrent aggression in a patient with temporal lobe epilepsy who had temporal lobectomy. Journal of Psychopharmacology (Oxford, England). 17: 350-1. PMID 14513930 DOI: 10.1177/02698811030173020 |
0.531 |
|
| 2003 |
Crippa J, Zuardi A, Busatto G, Hallak J, Sanches R, Santos A, Guimaraes F, Araujo D, Allen P, McGuire P. Clinical and psychophysiology correlates of a large cavum septum pellucidum in schizophrenia Schizophrenia Research. 60: 192. DOI: 10.1016/S0920-9964(03)81104-0 |
0.41 |
|
| 2002 |
Lopes-Machado EZ, De Souza Crippa JA, Hallak JEC, Guimarães FS, Zuardi AW. Electrodermically nonresponsive schizophrenia patients make more errors in the stroop color word test, indicating selective attention deficit Schizophrenia Bulletin. 28: 459-466. PMID 12645677 DOI: 10.1093/Oxfordjournals.Schbul.A006953 |
0.452 |
|
| 2001 |
Graeff FG, Silva M, Del Ben CM, Zuardi AW, Hetem LA, Guimarães FS. Comparison between two models of experimental anxiety in healthy volunteers and panic disorder patients. Neuroscience and Biobehavioral Reviews. 25: 753-9. PMID 11801299 DOI: 10.1016/S0149-7634(01)00055-0 |
0.447 |
|
| 2001 |
Del-Ben CM, Vilela JA, Hetem LA, Guimarães FS, Graeff FG, Zuardi AW. Do panic patients process unconditioned fear vs. conditioned anxiety differently than normal subjects? Psychiatry Research. 104: 227-37. PMID 11728612 DOI: 10.1016/S0165-1781(01)00312-2 |
0.455 |
|
| 2000 |
Monteiro-dos-Santos PC, Graeff FG, dos-Santos JE, Ribeiro RP, Guimarães FS, Zuardi AW. Effects of tryptophan depletion on anxiety induced by simulated public speaking. Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Mã©Dicas E Biolã³Gicas / Sociedade Brasileira De BiofãSica ... [Et Al.]. 33: 581-7. PMID 10775890 DOI: 10.1590/S0100-879X2000000500013 |
0.461 |
|
| 1996 |
Hetem LAB, de Souza CJ, Zuardi AW, Guimarães FS, Graeff FG. Effect ofd-fenfluramine on human experimental anxiety Psychopharmacology. 127: 276-282. DOI: 10.1007/BF02246136 |
0.42 |
|
| 1993 |
Zuardi AW, Cosme RA, Graeff FG, Guimarães FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. Journal of Psychopharmacology (Oxford, England). 7: 82-8. PMID 22290374 DOI: 10.1177/026988119300700112 |
0.491 |
|
| 1990 |
Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology. 100: 558-9. PMID 1969666 DOI: 10.1007/Bf02244012 |
0.487 |
|
| 1987 |
Guimarães FS, Zuardi AW, Graeff FG. Effect of chlorimipramine and maprotiline on experimental anxiety in humans. Journal of Psychopharmacology (Oxford, England). 1: 184-92. PMID 22158980 DOI: 10.1177/026988118700100305 |
0.484 |
|
| 1985 |
Graeff FG, Zuardi AW, Giglio JS, Lima Filho EC, Karniol IG. Effect of metergoline on human anxiety. Psychopharmacology. 86: 334-8. PMID 3929304 DOI: 10.1007/Bf00432224 |
0.683 |
|
| 1983 |
Karniol IG, Giampietro AC, Moura DS, Vilela WA, Oliveira MA, Zuardi AW. A double-blind study of the effect of L-dopa in psychotic patients with tardive dyskinesia | Estudo duplo-cego sobre a ação de L-dopa em pacientes psicóticos com discinesia tardia Acta Psiquiatrica Y Psicologica De America Latina. 29: 261-266. PMID 6369888 |
0.66 |
|
| 1983 |
Zuardi AW, Karniol IG. Effects on variable-interval performance in rats of Δ9-tetrahydrocannabinol and cannabidiol, separately and in combination Brazilian Journal of Medical and Biological Research. 16: 141-146. PMID 6317104 |
0.67 |
|
| 1982 |
Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects Psychopharmacology. 76: 245-250. PMID 6285406 DOI: 10.1007/BF00432554 |
0.692 |
|
| 1981 |
Zuardi AW, Finkelfarb E, Bueno OF, Musty RE, Karniol IG. Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol. Archives Internationales De Pharmacodynamie Et De Thã©Rapie. 249: 137-46. PMID 6261703 |
0.667 |
|
| 1977 |
Takahashi RN, Zuardi AW, Karniol IG. Chemical composition of Brazilian marihuana samples and the importance of several constituents to the pharmacological activity of the plant | Composição química e importância dos diversos constituintes na atividade farmacoloógica de amostras de Cannabis sativa brasileiras Revista Brasileira De Pesquisas Medicas E Biologicas. 10: 379-385. PMID 609775 |
0.633 |
|
| Show low-probability matches. |